Trial Profile
A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 06 Apr 2018 Planned End Date changed from 31 Dec 2017 to 17 May 2018.
- 06 Apr 2018 Planned End Date changed from 31 Dec 2017 to 17 May 2018.
- 19 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.